Dupilumab for the treatment of prurigo nodularis: A systematic review
Authors:
Open Access
- 20 January 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1092685
Abstract
Background: Conventional treatment techniques have limited efficacy and more side effects in the treatment of prurigo nodularis. The better alternative treatment option for better outcomes of the disease is dupilumab.Objective: The objective of this study was to systematically review dupilumab-related treatment outcomes in prurigo nodularis.Methods: Several databases like Embase, PubMed, Web of Science, and Cochrane library were searched for data acquisition on October 8, 2022. Based on Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, 24 publications were included in this study.Results: After 4,12,16 and more than 16 weeks of dupilumab treatment, 8.3% (n=5/60), 34.4% (n=11/32), 3.6% (n=2/56), and 45.3% (n=29/64) of patients had complete remission, respectively. In addition, 85.0% (n=51/60), 59.4% (n=19/32), 83.9% (n=47/56), and 43.8% (n=28/64) had partial remission, respectively. Moreover, 6.7% (n=4/60), 6.3% (n=2/32), 12.5% (n=7/56), and 10.9% (n=7/64) showed no remission, respectively, and significant reduction of numeric rating scale itch intensity (from 9.0 to 4.9, 2.1, 2.8, 0.9) was attained. There were no serious adverse events observed during treatment, but the most common event observed was conjunctivitis (12.6%, n=15/119).Conclusions: Dupilumab has definite effectiveness and safety in prurigo nodularis treatment.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO, identifier (CRD42022365802).Keywords
This publication has 45 references indexed in Scilit:
- Dramatic improvement of generalized prurigo nodularis with dupilumabJournal of the European Academy of Dermatology and Venereology, 2019
- Dupilumab Treatment for Generalized Prurigo NodularisJAMA Dermatology, 2019
- Reduced Itch Associated With Dupilumab Treatment In 4 Patients With Prurigo NodularisJAMA Dermatology, 2019
- Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitisBritish Journal of Dermatology, 2018
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaNew England Journal of Medicine, 2018
- Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic ItchCell, 2017
- European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigoJournal of the European Academy of Dermatology and Venereology, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2017
- Dupilumab Treatment in Adults with Moderate-to-Severe Atopic DermatitisNew England Journal of Medicine, 2014
- Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularisBritish Journal of Dermatology, 2011